Cargando…

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, defining resistance determinants is highly relevant for efforts to contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Sanne Brun, Fahnøe, Ulrik, Pham, Long V., Serre, Stéphanie Brigitte Nelly, Tang, Qi, Ghanem, Lubna, Pedersen, Martin Schou, Ramirez, Santseharay, Humes, Daryl, Pihl, Anne Finne, Filskov, Jonathan, Sølund, Christina Søhoel, Dietz, Julia, Fourati, Slim, Pawlotsky, Jean‐Michel, Sarrazin, Christoph, Weis, Nina, Schønning, Kristian, Krarup, Henrik, Bukh, Jens, Gottwein, Judith Margarete
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772116/ https://www.ncbi.nlm.nih.gov/pubmed/30964552 http://dx.doi.org/10.1002/hep.30647

Ejemplares similares

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals
por: Pihl, Anne F., et al.
Publicado: (2018)

SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor
por: Offersgaard, Anna, et al.
Publicado: (2021)

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro
por: Zhou, Yuyong, et al.
Publicado: (2021)

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication
por: Ramirez, Santseharay, et al.
Publicado: (2021)

High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor
por: Offersgaard, Anna, et al.
Publicado: (2022)

Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency
por: Czarnota, Anna, et al.
Publicado: (2020)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization
por: Pham, Long V., et al.
Publicado: (2022)

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
por: Underwood, Alexander P., et al.
Publicado: (2021)

Identification of novel neutralizing determinants for protection against HCV
por: Alzua, Garazi P., et al.
Publicado: (2023)

An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
por: Offersgaard, Anna, et al.
Publicado: (2023)

Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine
por: Lothert, Keven, et al.
Publicado: (2020)

Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA–mRNA or Vector–mRNA COVID-19 Vaccines
por: Sølund, Christina, et al.
Publicado: (2022)

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication
por: Fahnøe, Ulrik, et al.
Publicado: (2022)

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
por: Zhou, Yuyong, et al.
Publicado: (2022)

Nationwide Experience of Treatment with Protease Inhibitors in Chronic Hepatitis C Patients in Denmark: Identification of Viral Resistance Mutations
por: Sølund, Christina, et al.
Publicado: (2014)

In vitro efficacy of artemisinin-based treatments against SARS-CoV-2
por: Zhou, Yuyong, et al.
Publicado: (2021)

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination
por: Underwood, Alexander P., et al.
Publicado: (2023)

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
por: Gammeltoft, Karen A., et al.
Publicado: (2021)

High recombination rate of hepatitis C virus revealed by a green fluorescent protein reconstitution cell system
por: Galli, Andrea, et al.
Publicado: (2021)

Virologic Tools for HCV Drug Resistance Testing
por: Fourati, Slim, et al.
Publicado: (2015)

Recent advances in understanding and diagnosing hepatitis B virus infection
por: Fourati, Slim, et al.
Publicado: (2016)

Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1–3 Strains and Does Not Correlate with Virus Replication
por: Galli, Andrea, et al.
Publicado: (2021)

Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome
por: Pedersen, Jannie, et al.
Publicado: (2013)

Genome Sequence of an Unknown Subtype of Hepatitis C Virus Genotype 6: Another Piece for the Taxonomic Puzzle
por: Pedersen, Martin Schou, et al.
Publicado: (2019)

Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment
por: Pedersen, Martin S., et al.
Publicado: (2021)

HCV p7 as a novel vaccine-target inducing multifunctional CD4(+) and CD8(+) T-cells targeting liver cells expressing the viral antigen
por: Filskov, Jonathan, et al.
Publicado: (2019)

SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients
por: Fourati, Slim, et al.
Publicado: (2020)

Breakthrough Covid‐19 infections in vaccinated recipients of allogeneic stem cell transplantation
por: Fourati, Slim, et al.
Publicado: (2022)

Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model
por: Galli, Andrea, et al.
Publicado: (2018)

Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412–425 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles
por: Czarnota, Anna, et al.
Publicado: (2023)

Persistent SARS-CoV-2 Alpha Variant Infection in Immunosuppressed Patient, France, February 2022
por: Fourati, Slim, et al.
Publicado: (2022)

Virus Adaptation and Selection Following Challenge of Animals Vaccinated against Classical Swine Fever Virus
por: Fahnøe, Ulrik, et al.
Publicado: (2019)

Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens
por: Prentoe, Jannick, et al.
Publicado: (2021)

Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon
por: Ward, Joseph C., et al.
Publicado: (2020)

Productive Homologous and Non-homologous Recombination of Hepatitis C Virus in Cell Culture
por: Scheel, Troels K. H., et al.
Publicado: (2013)

Performance of 22 Rapid Lateral Flow Tests for SARS-CoV-2 Antigen Detection and Influence of “Variants of Concern”: Implications for Clinical Use
por: Gourgeon, Aurélie, et al.
Publicado: (2022)

Myocardial perfusion reserve in patients with chronic hepatitis C before and after direct‐acting antiviral treatment—a pilot study
por: Sølund, Christina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_grqvsnrt6i09ljmouom30vh97s